Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer

International Journal of Biological Sciences

Volumn 3, Issue 7, 2007, Pages 455-462

  Li, Qiao ^a,d   Iuchi, Takekazu ^a,b   Jure Kunkel, Maria N ^c   Chang, Alfred E ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Adoptive immunotherapy; Anti 4 1BB; Cancer; NK cells; STAT4; T cells

Indexed keywords

CD3 ANTIBODY; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 IBB; MONOCLONAL ANTIBODY CD28; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CELL STIMULATION; CELL SURVIVAL; CELL THERAPY; CELL TRANSFER; CONGENIC STRAIN; CONTROLLED STUDY; EFFECTOR CELL; ENZYME ACTIVATION; FEMALE; IN VITRO STUDY; LUNG METASTASIS; LYMPH NODE; MOUSE; NATURAL KILLER CELL; NONHUMAN; T LYMPHOCYTE; TUMOR REGRESSION; WILD TYPE;

MUS;

EID: 37249088549     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.3.455     Document Type: Article

References (38)

1. Chang AE, Li Q, Jiang G, et al. Phase II trial of autologous tumor vaccination, Anti-CD3-activated vaccine-primed lymphocytes, and Interleukin-2 in stage IV renal cell cancer. J Clin Oncol. 2003;21:884-890.
2. Topalian SL, Solomon D, Avis FP, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol. 1988;6:839-853.
3. Ganss R, Ryschich E, Klar E, et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002;62:1462-1470.
4. Huang H, Li F, Gordon JR, et al. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Cancer Res. 2002;62:2043-2051.
5. Lou Y, Wang G, Lizée G, et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 2004;64:6783-6790.
6. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501-6505.
7. Kwon BS, Tan KB, Ni J, et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem. 1997;272:14272-14276
8. Wilcox RA, Chapoval AI, Gorski KS, et al. Expression of functional CD137 receptor by dendritic cells. J Immunol.. 2002;168: 4262-4267.
9. Takahashi C, Mittler RS, Vella AT. Differential clonal expansion of CD4 and CD8 T cells in response to 4-1BB ligation: contribution of 4-1BB during inflammatory responses. Immunol Letters. 2001; 76:183-191.
10. Lee HW, Park SJ, Choi BK, et al. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol. 2002;169:4882-4888.
11. Li Q, Carr A, Ito F, et al. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res. 2003;63:2546-2552.
12. Numbenjapon T, Serrano LM, Chang WC, et al. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells. Exp Hematol. 2007;35:1083-1090.
13. van Rijn RS, Simonetti ER, Hagenbeek A, et al. Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality. Exp Hematol. 2007;35:117-127.
14. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Med. 1997;3:682.
15. McMillin DW, Hewes B, Gangadharan B, et al. Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy. Hum Gene Ther. 2006;17:798-806.
16. Li Q, Pan PY, Gu P, et al. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res. 2004;64:1130-1139.
17. Lee SJ, Rossi RJ, Lee SK, et al. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent. J Immunol. 2007;179:2203-2214.
18. Takahashi C, Mittler RS, Vella AT. 4-1BB is a bona fide CD8T cell survival signal. J Immunol. 1999;162:5037-5040.
19. Wilcox, R., Flies D, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. Clin Invest. 2002;109:651-659.
20. Ito F, Li Q, Shreiner AB, et al. Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines. Cancer Res. 2004;64:8411-8419.
21. Zhang S, Kaplan MH. The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-gamma expression. J Immunol. 2000;165:1374-1380.
22. Miller RE, Jones J, Le T, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol. 2002;169:1792-1800.
23. Taraban VY, Rowley TF, O'Brien L, et al. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol. 2002;32:3617-3627.
24. Wang G, Tschoi M, Spolski R, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 2003;63:9016-9022.
25. Brady J, Hayakawa Y, Smyth MJ, et al. IL-21 induces the functional maturation of murine NK cells. J Immunol. 2004;172:2048-2058.
26. Wilcox R, Tamada K, Strome S, et al. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol. 2002;169:4230-4236.
27. Yang Y, Yang S, Ye Z, et al. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment. Cancer Res. 2007;67:2339-2344.
28. Halstead ES, Mueller YM, Altman JD, et al. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol. 2002;3:536-541.
29. Cooper D, Bansal-Pakala P, Croft M. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur J Immunol. 2002;32: 521-529.
30. Laderach D, Movassagh M, Johnson A, et al. 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Internatl Immunol. 2002;14:1155-1167.
31. Lee H-W, Nam K-O, Seo SK, et al. 4-1BB cross-linking enhances the survival and cell cycle progression of CD4T lymphocytes. Cell Immunol. 2003;223:143-150.
32. Lee H-W, Park S-J, Choi BK, et al. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xl and Bfl-1. J Immunol. 2002;169:4882-4888.
33. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncology. 2005;23:2346-2357.
34. Kroon H, Li Q, Teitz -Tennenbaum S, et al. 4-1BB co-stimulation of effectror T cells for adoptive immunotherapy of cancer: Involvement of Bcl gene family members. J Immunotherapy. 2007;30:406-416.
35. Aruga A, Aruga E, Tanigawa K, et al. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol. 1997;159:664-673.
36. Stamm LM, Satoskar AA, Ghosh SK, et al. STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. Eur J Immunol. 1999;29:2524-2529.
37. Chen Z, Lund R, Aittokallio T, et al. Identification of novel IL-4/Stat6 regulated genes in T lyphocytes. J Immunol. 2003;171:3627-3635.
38. Stamm LM, Taisanen-Sokolowski A, Okano M, et al. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J Immunol. 1998;161:6180-6188.